Execs On The Move, January 2015
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Advertisement
Topics
- Industries
- BioPharmaceutical
- Medical Device
Related Companies
- Ambu AS
- Gilead Sciences Inc.
- Amarantus BioScience Holdings Inc.
- Ardelyx Inc.
- Neogen Corp.
- WuXi NextCODE Genomics
- Nivalis Therapeutics Inc.
- Dimension Therapeutics Inc.
- Invuity Inc.
- Idera Pharmaceuticals Inc.
- Intrexon Corp.
- NxThera Inc.
- Pulmonx Corp.
- Catabasis Pharmaceuticals Inc.
- Dimension Therapeutics Inc.
- Invuity Inc.
- Bellicum Pharmaceuticals Inc.
- Genocea Biosciences Inc.
- Echo Therapeutics Inc.
- Osiris Therapeutics Inc.
- BioClinica
- Zealand Pharma AS
- MRI Interventions Inc.
- Klox Technologies Inc.
- Idera Pharmaceuticals Inc.
- Millendo Therapeutics Inc.
- Axcella Health Inc.
- Bellicum Pharmaceuticals Inc.
- Translate Bio Inc.
- Milestone Scientific Inc.
- Agilis Biotherapeutics LLC
- Greer Laboratories Inc.
- Cellectar Biosciences Inc.
- Anterios Inc.
- Strongbridge Biopharma PLC
- Apricus Biosciences Inc.
- Atossa Genetics Inc.
- NinePoint Medical Inc.
- IntriCon Corp.
- Retrophin Inc.
- Ocera Therapeutics Inc.
- Merus Labs International Inc.
- MRI Interventions Inc.
- Cantel Medical Corp.
- Aquestive Therapeutics Inc.
- ARCA biopharma Inc.
- Acucela Inc.
- Vermillion Inc.
- Cubist Pharmaceuticals Inc.
- Klox Technologies Inc.
- Cytovance Biologics Inc.
- Arno Therapeutics Inc.
- Biolase Inc.
- Apricus Biosciences Inc.
- ARCA biopharma Inc.
- H. Lundbeck AS
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IV004298
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
IV004298
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.